Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.99M
Average 0.34M
ANRO Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Alto Neuroscience, Inc.NYSE: ANRO
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $556K (cash outflow) rose 2216.7% year over year, ahead of the -70.3% change in trailing-twelve-month capital expenditures. Over 3 fiscal years it compounded at -68.0% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +2216.7% holds above the trailing-twelve-month pace of -70.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (24K) USD
- Year-over-year change
- +98.8%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (24K) | +98.8% |
| FY2024 | 2024-12-31 | (2.08M) | -341.5% |
| FY2023 | 2023-12-31 | (470K) | +35.8% |
| FY2022 | 2022-12-31 | (732K) | -7.6% |
| FY2021 | 2021-12-31 | (680K) | — |
Capital Expenditures vs competitors
How ANRO compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -70.3% is the 6th highest of 8, against a peer median of -8.4%.
- Over three fiscal years its annual growth of -68.0% compares with a peer median of -7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.69M USD | +140168207.3% | — | 7.8% | |
| LTM Dec 2025 | $6.08M USD | — | +88.7% | — | |
| LTM Mar 2026 | $2.23M USD | -44.0% | -1.0% | 3.3% | |
| LTM Mar 2026 | $928K USD | -8.4% | -10.9% | — | |
| LTM Dec 2025 | CHF 900.16K CHF | +56.3% | -11.5% | 25.2% | |
| LTM Mar 2026 | $556K USD | -70.3% | -68.0% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $496K USD | +19.8% | +25.1% | — |
| LTM Mar 2026 | $420K USD | -96.6% | -53.7% | 10.9% | |
| LTM Mar 2026 | $106K USD | — | -53.4% | 11.5% | |
| LTM Mar 2026 | $42K USD | -92.6% | -3.1% | — | |
| LTM Mar 2026 | $4 USD | — | — | — | |
| Peer median (excluding ANRO) | — | -8.4% | -7.0% | 10.9% | |
Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Depreciation & Amortization | 145K | 342K | 373K | 502K | 661K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 227K | 1.76M | 2.89M | 7.63M | 8.11M |
| Change in Working Capital | (572K) | 4.58M | (698K) | 4.06M | 33K |
| Accounts Receivables | (1.29M) | 1.16M | 325K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 458K | 1.01M | (632K) | 516K | 221K |
| Other Working Capital | 255K | 2.42M | (391K) | 3.54M | (188K) |
| Other Non-Cash Items | 125K | 632K | 291K | 1.81M | 2.67M |
| Operating Cash Flow | (9.26M) | (20.39M) | (33.45M) | (47.42M) | (51.77M) |
| Capital Expenditures | (680K) | (732K) | (470K) | (2.08M) | (24K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (680K) | (732K) | (470K) | (2.08M) | (24K) |
| Debt Repayment | 0 | 9.83M | 0 | 1.25M | 9.48M |
| Common Stock Issued | 7K | 43K | 181K | 137.58M | 50.7M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (167K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (205K) | (341K) | (2.05M) | (3.14M) | 67K |
| Financing Cash Flow | 31.69M | 43.79M | 68.13M | 135.69M | 60.08M |
| Effect of Forex Changes | (50K) | (24K) | (8K) | (11K) | (30K) |
| Net Change in Cash | 21.7M | 22.64M | 34.2M | 86.18M | 8.26M |
| Free Cash Flow | (9.94M) | (21.13M) | (33.92M) | (49.5M) | (51.79M) |
Alto Neuroscience, Inc.
NYSE:ANRO
Intrinsic Alpha fair value
Locked
Current Price
$25.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.